Medpace Authorizes $1 Billion Buyback and Reports Higher Third-Quarter Profit
Medpace’s board approved a new $1 billion stock buyback authorization, effective through 2028, replacing an authorization with $527 million remaining. The company also reported higher third-quarter profit.